The advent of urosepsis was profound at the selected time interval of therapy, as evidenced by hypothermia, decrease of oxygen saturation and leucopenia.
Accordingly, the chest computed tomography (CT) scans were performed at baseline and at three cycles (every 12-week interval) of therapy to determine the status of the disease.
Obviously, the present study has some drawbacks, such as the limited number of patients and the scatter in the intervals of determining therapy response.
Accordingly, chest computed tomography (CT) scans were routinely performed at baseline and at three time points (at 12-week intervals) of adjunctive therapy to determine the status of the disease.
Overall, it seems that patients who may be candidates for discontinuation or a possible extension of infusion intervals of infliximab therapy have a better outcome if this decision is made while the patients are in a state of low disease activity.
In this cohort, among various characteristics, including the dose and interval of CHOP therapy, only the mean peak leucocyte count (MPLC) with each therapy cycle was associated with development of this toxicity (MPLC > or = 23.0 x 10 9) l -1), 6 out of 29 cases; MPl -1 23.0 x 10(9) l(-1), 0 out of 23 cases; P = 0.020).
In our series where bone transport was performed after resection for infection, we inserted the intramedullary nails after an interval of antibiotic therapy.
For each covariate, we report the odds ratio (and 95% confidence interval) of receiving therapy.
Treatment duration was the time on appropriate anti-tuberculous therapy, and the time of post treatment follow-up was defined as the interval between cessation of therapy and the last known contact with the patient.
Future randomized studies are needed to determine the optimal dosage, dose interval and duration of therapy in refractory multisystemic sarcoidosis.
